BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Aegle Therapeutics

Aegle Therapeutics logo

Clinical Trials

Aegle Therapeutics is a first-in-class, phase 1/2a biotechnology company isolating extracellular vesicles including exosomes ("EVs") secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa ("DEB"), a rare genetic pediatric connective tissue disorder. Aegle's EV therapy, using its proprietary platform isolation technology, is cell-free and has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle's EVs deliver COL7, COL7A1 mRNA and then regenerative signals of MSCs to diseased cells and present a unique, multifaceted approach to DEB. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can accelerate and enhance healing, reduce scarring, minimize contraction and improve overall cosmesis.

Posts Mentioning This Company

15 Biopharma Research Trends to Watch in 2022

Table of contents:    mRNA vaccines and RNA therapies  Epitranscriptomics Targeting RNA with small molecules Deep learning and big data in drug discovery Neoantigens Theranostics  Exosomes Synthetic Biology 3D Bioprinting Antibiotics “anti-trend” (and hope?) Nanotechnologies in Drug Delivery Gene Editing (CRISPR-Cas9) Aging research  Microbiome  Protein Degraders   Discoveries made in …